GeneXpert® breast cancer STRAT4 assay demonstrates high concordance of ESR1, PgR, HER2, and Ki67 with central IHC and FISH testing in FFPE breast tumor tissues

The Breast ◽  
2017 ◽  
Vol 32 ◽  
pp. S49 ◽  
Author(s):  
E. Wong ◽  
N. Wu ◽  
B. Acca ◽  
H. Dias
Keyword(s):  
Breast Cancer ◽  
Breast Tumor ◽  
Tumor Tissues ◽  
High Concordance

scholarly journals The role of Ghrelin Receptor Expression in the Diagnosis of breast cancer

2020 ◽  
Vol 11 (2) ◽  
pp. 1438-1446
Author(s):  
Abbas M. Ajeed ◽  
Alaa G. Hussein ◽  
Nazar Alwakeel ◽  
Omar F. Abdul-Rasheed
Keyword(s):  
Breast Cancer ◽  
Breast Tumor ◽  
Breast Tumors ◽  
Receptor Expression ◽  
Tissue Samples ◽  
Ghrelin Receptor ◽  
Female Patients ◽  
Benign Breast Tumor ◽  
Tumor Tissues

To determine the possible role of the assessment of Ghrelin receptor expression in breast tissues as a tool for the diagnosis of breast cancer and differentiate it from a benign breast tumor. A case-control study was done on 60 female patients with breast cancer and 60 female patients with benign breast tumors (Fibroadenoma) who were recruited from Al Imamain Al-Kadhemain Medical City and Oncology teaching Hospital, Baghdad, Iraq between May 2018 and December 2018. Immunohistochemical staining was done on the breast tissue samples obtained from patients and compared with the control group, which comprised 75 fibrocystic tissue samples obtained from age, BMI and sex-matched females. The degree of Ghrelin Receptor expression was determined immunohistochemically. The expression of Ghrelin receptors in breast malignant tumor tissues was higher than that in benign breast tumor tissues and controls, in addition to that, results obtained from all groups revealed that Ghrelin receptor intensity and its expression proportion were strongly and significantly associated with the type of tissues. The expression of the Ghrelin receptor can be considered as a highly significant immunohistochemical marker for the detection of breast tumors and for the differentiation between both types of tumors; benign and malignant.

scholarly journals Long non-coding RNA UCA1 promotes breast cancer by upregulating PTP1B expression via inhibiting miR-206

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Yi Li ◽  
Qingan Zeng ◽  
Jiliang Qiu ◽  
Ting Pang ◽  
Jianzhong Xian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Tumor ◽  
Breast Cancer Cells ◽  
Transcriptional Level ◽  
Normal Tissues ◽  
Non Coding Rna ◽  
Tumor Tissues ◽  
Breast Tissues ◽  
Long Non Coding Rna

Abstract Background The long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) is involved in various cancers and often functions through microRNAs. The pro-survival protein PTP1B is known to play important roles in cancer development. However, the connection between UCA1 and PTP1B in breast cancer is not well studied. Methods In this study, we first evaluated the correlation between UCA1 level and PTP1B expression in breast tissues, which showed the expression of PTP1B were much higher in the breast tumor tissues than in the peritumor normal tissues. The UCA1 level was positively associated with PTP1B expression in breast tumor tissues. Results We observed that UCA1 could up-regulate PTP1B expression in breast cancer cells. We also found that miR-206 could inhibit the expression of PTP1B by directly binding to the 3′-UTR of its mRNA. Interestingly, UCA1 could increase the expression of PTP1B through sequestering miR-206 at post-transcriptional level. The results also suggested that UCA1-induced PTP1B expression facilitated the proliferation of breast cancer cells. Conclusions We conclude that UCA1 can up-regulates PTP1B to enhance cell proliferation through sequestering miR-206 in breast cancer. Our finding provides new insights into the mechanism of breast cancer regulation by UCA1, which could be a potential target for breast cancer treatment. Trial registration 2012N5hSYSU48573. Registered at Oct 12, 2012

scholarly journals Association of XRCC1 Trp194 allele with risk of breast cancer, and Ki67 protein status in breast tumor tissues

2016 ◽  
Vol 37 (6) ◽  
pp. 624-630 ◽  
Author(s):  
Chiya Jalali ◽  
Bayazid Ghaderi ◽  
Sabrieh Amini ◽  
Mohammad Abdi ◽  
Daem Roshani
Keyword(s):  
Breast Cancer ◽  
Breast Tumor ◽  
Protein Status ◽  
Tumor Tissues

scholarly journals The high expression of NUDT5 indicates poor prognosis of breast cancer by modulating AKT / Cyclin D signaling

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0245876
Author(s):  
He Zhang ◽  
Li-Qun Zhang ◽  
Cheng-Cheng Yang ◽  
Jin Li ◽  
Xin-Yuan Tian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Breast Tumor ◽  
Poor Prognosis ◽  
High Expression ◽  
Breast Cancer Cell Lines ◽  
Cyclin D ◽  
Tumor Tissues

NUDIX hydrolase type 5 (NUDT5) is a kind of ADP-ribose pyrophosphatase and nucleotide metabolizing enzyme in cell metabolism. Previous studies have shown NUDT5 expression affected chromosome remodeling, involved in cell adhesion, cancer stem cell maintenance and epithelial to mesenchyme transition in breast cancer cells. Nevertheless, the role of NUDT5 in breast cancer progression and prognosis has not yet been systematically studied. This study explored the association of NUDT5 with the tumor development and poor prognosis in patients with breast cancer. Our results show that the levels of NUDT5 were upregulated in breast cancer cell lines and breast tumor tissues, and the expression of NUDT5 in breast tumor tissues increased significantly when compared with adjacent non-tumorous tissues by immunohistochemical staining of tissue microarrays. Breast cancer patients with high NUDT5 expression had a worse prognosis than those with low expression of NUDT5. In addition, the knockdown of NUDT5 suppressed breast cancer cell lines proliferation, migration and invasion, and dramatically inhibited the AKT phosphorylation at Thr308 and expression of Cyclin D1. The opposite effects were observed in vitro following NUDT5 rescue. Our findings indicated that the high expression of NUDT5 is probably involved in the poor prognosis of breast cancer via the activation of the AKT / Cyclin D pathways, which could be a prognostic factor and potential target in the diagnosis and treatment of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document